JBJosip Bago

Josip Bago

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Josip Bago has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication

    by Marinko Marušić, Lucija Dominković, Karolina Majstorović Barać, Saša Gulić, Josip Bago, Davorin Pezerović

    Article: Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication - Minerva Gastroenterologica e Dietologica 2017 June;63(2):80-4 - Minerva Medica - Journals


  • Open Access

    Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial

    by Josip Bago, Karolina Majstorović, Željka Belošić-Halle, Nastja Kućišec, Vinko Bakula, Monika Tomić, Petra Bago, Rosana Troskot

    Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments.


  • Open Access

    Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial

    by Josip Bago, Branko Pevec, Monika Tomić, Marinko Marušić, Vinko Bakula, Petra Bago

    BACKGROUND: In eradication of Helicobacter pylori infection, standard quadruple second-line therapy consisting of proton pump inhibitor (PPI), bismuth, metronidazole and tetracycline often fails and shows poor patient compliance. The aim of our study was to evaluate the efficacy and tolerability of moxifloxacin-based triple therapy as an alternative second-line protocol. METHODS: A total of 160 patients, in whom the initial standard PPI triple therapy had failed to eradicate H. pylori infection, were included in the study. The initial H. pylori status was assessed using the ^13C-urea breath test. Patients were randomized to one of the following 7-day treatment regimens: (1) OMM: omeprazole 20 mg twice a day, moxifloxacin 400 mg/day, metronidazole 500 mg three times a day; and (2) OBMT: omeprazole 20 mg twice a day, colloidal bismuth subcitrate 120 mg four times a day, metronidazole 500 mg three times a day, tetracycline 500 mg four times a day. Patient compliance and adverse events were evaluated one week after completion of therapy. H. pylori status was re-assessed with the ^13C-urea breath test six weeks after the end of therapy. RESULTS: The eradication rates were 73.2% (60/82) and 78.9% (60/76) with moxifloxacin-based triple therapy, and 53.8% (42/78) and 64.6% (42/65) with bismuth-based quadruple therapy, by intention-to-treat ( p = 0.018) and per-protocol ( p = 0.088) analyses, respectively. Adverse events/intolerability were described in 12/82 patients in the OMM group and 18/78 patients in the OBMT group. Compliance with treatment was 92.7% in the OMM group and 83.3% in the OBMT group. CONCLUSION: Moxifloxacin-based triple therapy is a highly effective second-line eradication treatment in H. pylori infection. Because of its high levels of safety and tolerability, this protocol represents an adequate alternative to the standard bismuth-based quadruple therapy. HINTERGRUND DER STUDIE: Die Standard-Quadruple-Second-Line-Therapie zur Eradikation einer Helicobacter pylori (Hp) Infektion, bestehend aus einem Protonenpumpen-Hemmer (PPI), Bismuth, Metronidazol und Tetracyclin versagt häufig, wobei die Patienten oft eine schlechte Compliance bei dieser Therapie zeigen. Ziel der vorliegenden Studie war es, die Wirksamkeit und Verträglichkeit einer Moxifloxacin-basierten Triple Therapie als alternatives Second-Line-Protokoll zu untersuchen. METHODEN: 160 Patienten, bei denen die initiale Standard PPI-Triple-Therapie zur Eradikation einer Infektion mit Hp versagt hatte, wurden in die Studie aufgenommen. Der ursprüngliche Hp-Status wurde durch den C13-Urea-Atemtest erhoben. Die Patienten wurden zu folgenden 7-Tages Therapieschemata randomisiert: 1) "OMM": Omeprazol 20 mg 2 × tgl., Moxifloxacin 400 mg/Tag, Metronidazol 500 mg 3 × tgl; 2) "OBMT": Omeprazol 20 mg 2 × tgl., kolloidales Bismuth Subzitrat 120 mg 4 × tgl., Metronidazol 500 mg 3 × tgl., Tetrazyklin 500 mg 4 × tgl. Eine Woche nach Ende der Therapie wurde durch Pillenzählen die Compliance überprüft und nach Nebenwirkungen gefragt. Der Hp-Status wurde durch den C13-Urea-Atemtest 6 Wochen nach Ende der Therapie reevaluiert. ERGEBNISSE: Folgende Eradikationsraten wurden erhoben: Für die mit dem OMM-Schema behandelten Patienten: 73,2% (60/82 – intention to treat) bzw. 78,9% (60/76 per-Protokoll-Analyse). Für die mit dem OBMT-Schema behandelten Patienten: 53,8% (42/78 intention to treat; p = 0.018 im Vergleich zu OMM) bzw. 64,6% (42/65 per Protokoll, p = 0.088 im Vergleich zu OMM). Nebenwirkungen und/oder Unverträglichkeit wurden von 12 der 82 OMM Patienten bzw. von 18 der 78 OBMT Patienten angegeben. Die Compliance betrug 92,7% in der OMM Gruppe und 83,3% in der OBMT Gruppe. SCHLUSSFOLGERUNGEN: Die Moxifloxacin-basierte Triple-Therapie ist eine sehr wirksame second-line Behandlung zur Eradikation einer Hp Infektion. Auf Grund der hochgradigen Sicherheit und guten Verträglichkeit stellt dieses Protokoll eine adäquate Alternative zur bisherigen Bismuth-basierten Standard-Therapie dar.


  • High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial

    by Petra Bago, Aleksandar Vcev, Monika Tomic, Marjan Rožankovic, Marinko Marušić, Josip Bago

    EINLEITUNG: In der klinischen Praxis stellt die Eradikation von Helikobacter pylori (HP) noch immer eine problematische Therapie dar. Ziel ist, eine hohe Eradikationsrate zu einem niedrigen Preis zu erzielen; die derzeitigen Behandlungsmöglichkeiten geben uns dazu die Möglichkeit. Kürzlich veröffentlichte Resultate mit einer auf Moxifloxacin basierten Therapie zeigten eine niedrige Resistenzrate und eine gute Kompliance. Die vorliegende Studie untersucht die Wirksamkeit des Einsatzes von Moxifloxacin im Rahmen einer Triple-Therapie zur Eradikation von HP. ZIEL UND METHODEN: Ziel unserer Studie war es, die Wirksamkeit einer einwöchigen Moxifloxacin-basierten HP-Eradikationstherapie mit der Standard-Therapie zur vergleichen. 277 HP-positive Patienten mit einer Dyspepsie ohne Ulcus wurden in 4 Gruppen randomisiert: MML Gruppe: Moxifloxacin 400 mg/Tag, Metronidazol 2 × 400 mg/Tag, Lansoprazol 30 mg 2 × tgl; MAL Gruppe: Moxifloxacin 400 mg/Tag, Amoxicillin 1 g 2 × tgl, Lansoprazol 30 mg 2 × tgl; CML Gruppe: Clarithromycin 500 mg 2 × tgl., Metronidazol 400 mg 2 × tgl, Lansoprazol 30 mg 2 × tgl; und die CAL Gruppe: Clarithromycin 500 mg 2 × tgl, Amoxicillin 1 g 2 × tgl, Lansoprazol 30 mg 2 × tgl. Zur Erfassung der Prävalenz des HP wurden die Patienten mittels dem CLO Test untersucht. Außerdem wurde vor der Randomisierung und 4–6 Wochen nach Ende der Therapie gastroskopisch eine Histologie gewonnen und eine Kultur angelegt. Die bakterielle Empfindlichkeit auf Clarithromycin und Moxifloxacin wurden durch den E-Test bestimmt. ERGEBNISSE: 265 Patienten (95,6%) vollendeten die Studie. Die HP-Eradikationsrate war entsprechend der ITT und der PP Analysen in der MML Gruppe 93,5% (58/62) und 96,7% (58/60); in der MAL Gruppe 86,4% (57/66) und 90,5% (57/63), in der CML Gruppe 70,4% (50/71) und 75,8% (50/66) sowie in der CAL Gruppe 78,2% (61/78) sowie 80,2% (61/76). Die Behandlungsprotokolle mit Moxifloxacin waren waren sowohl in der ITT als auch in der PP Analyse signifikant erfolgreicher als die Clarithromycin-basierten Therapieregimes. Von den 238 Patienten (86% der gesamten Studiengruppe) waren 10,8% primär gegen Clarithromycin und 5,9% primär gegen Moxifloxacin resistent. Die Eradikation der Moxifloxacin-sensitiven/resistenten Keimstämme lag bei 98,1/75% für das MML (p < 0,01) und bei 99,1/66,7% für das MAL Regime (p = n.s.), verglichen mit dem Erfolg bei Moxifloxacin-sensitiven Stämmen von 98,1/91,1% (p < 0,05) bzw. Moxifloxacin-resistenten von 75/66,7% (p = n.s.) für die MML und MAL Gruppen. Die Behandlungsprotokolle mit Clarithromycin unterschieden sich bezüglich ihrer Wirksamkeit, sensitive oder resistente Keimstämme zu eradizieren, nicht signifikant. SCHLUSSFOLGERUNG: Triple-Therapien mit Moxifloxacin zeigten höhere Eradikationsraten mit weniger Nebenwirkungen als die bisherige Standardtherapie, sowie eine gute Kompliance. Außerdem macht die zunehmende Prävalenz der Resistenz gegenüber Clarithromycin Moxifloxacin-basierte Therapieprotokolle wahrscheinlich zu einer wirksamen und sicheren Option zur Behandlung einer Infektion mit HP. INTRODUCTION: Eradication of Helicobacter pylori remains a problematic treatment issue in clinical practice. The intention is to find a treatment that achieves a high rate of eradication at a low price and treatment options that are now used give us the opportunity to achieve this goal. Recently published results showing a low rate of resistance and better compliance with moxifloxacin-based treatment regimens indicate the need to investigate its efficacy in H. pylori eradication. This study is based on proving the efficacy of moxifloxacin in H. pylori eradication within the triple therapy. AIMS AND METHODS: The aim of the study was to compare the efficacy of one week of moxifloxacin-based treatment with the standard treatment for H. pylori eradication. Patients with H. pylori infection and non-ulcer dyspepsia (n = 277) were randomly divided into four groups to receive: moxifloxacin 400 mg/d, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily (MML group); moxifloxacin 400 mg/d, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily (MAL group); clarithromycin 500 mg twice daily, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily (CML group); clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily (CAL group). The patients were assessed for prevalence of H. pylori using the CLO test, histology and culture on gastric biopsy samples obtained during upper gastrointestinal endoscopy before randomization and 4–6 weeks after completion of treatment. Bacterial sensitivity to clarithromycin and moxifloxacin was determined with the E-test. RESULTS: 265 (95.6%) patients completed the study forming the basis for PP analysis. Eradication rates of H. pylori in ITT and in PP analyses were: in the MML group 93.5% (58/62) and 96.7% (58/60), respectively; in the MAL group 86.4% (57/66) and 90.5% (57/63); in the CML group 70.4% (50/71) and 75.8% (50/66); and in the CAL group 78.2% (61/78) and 80.2% (61/76). Moxifloxacin treatment protocols were significantly more effective on both ITT and PP analyses than the clarithromycin based protocols with only one exception (MAL vs. CAL on ITT analysis). Among 238 patients (86% of the entire study group), strains showing primary resistance to clarithromycin were found in 10.8% and to moxifloxacin in 5.9%. Eradication of moxifloxacin sensitive/resistant strains was 98.1%/75% for MML (p < 0.01) and 91.1%/66.7% for MAL (p = n.s.); comparison of eradication of sensitive strains in MML and MAL regimens was 98.1%/91.1% (p < 0.05), and for resistant strains 75%/66.7% (p = n.s.). CML and CAL protocols did not differ in efficacy of eradication of clarithromycin sensitive or resistant strains. CONCLUSION: Moxifloxacin-based triple therapies showed higher eradication rates with few side effects and good drug compliance when compared with standard H. pylori treatments. Moreover, the increased prevalence of clarithromycin resistance suggests that moxifloxacin-based regimens could be safe and effective options in treatment of H. pylori infection.


    • 28 June 2002
      • Vol. 114  (12) , 448-53

    The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.

    by Josip Bago, Zeljka Belosić Halle, Dean Strinić, Nastja Kućisec, Dubravka Jandrić, Milenko Bevanda, Monika Tomić, Ante Bilić

    To compare ranitidine bismuth citrate with omeprazole as to their efficacy to eradicate H. pylori in two different treatment schedules both consisting of a combination of either of above with two antibiotics for 1 week, and to relate these treatment results to primary antibiotic resistance. 256 H. pylori positive patients with non-ulcer dyspepsia were randomised to one of the following four treatment groups: omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA); omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM). All drugs were given twice daily for one week. The patients were assessed for prevalence of H. pylori by CLO test, histology and culture on gastric biopsy samples obtained during upper gastrointestinal endoscopy before randomisation and 4-6 weeks after completion of therapy. Bacterial sensitivity to clarithromycin, metronidazole and amoxycillin was determined by E-test. On per-protocol analysis, overall eradication rates were 96% for RBCCA vs. 85% for OCA (p = 0.03), and 95% for RBCCM vs. 79% for OCM (p = 0.01). Amongst the 196 patients (77% of the entire study group) in whom antibiotic sensitivity testing was technically feasible, primary resistance was found in 8% for clarithromycin, in 33% for metronidazole, and in 0% for amoxycillin. Eradication of clarithromycin sensitive/resistant strains was 89%/40% for OCA (p = 0.0042) and 98%/80% for RBCCA (p = 0.0428). When strains were sensitive to both antibiotics, cure rates with OCM/RBCCM were 87%/96% respectively (p = 0.39), for strains resistant to clarithromycin only, eradication was achieved in 82% with OCM vs. 94% with RBCCM (p = 0.2), and in the case of metronidazole resistance in 85% with OCM vs. 94% with RBCCM (p = 0.09). Ranitidine bismuth citrate in combination with clarithromycin and either metronidazole or amoxycillin produced higher eradication rates than omeprazole co-administered with the same antibiotics. This appeared especially prominent in the subgroups with clarithromycin resistance without, however, reaching statistical significance. Efficacy of neither eradication regimen was influenced by metronidazole sensitivity to a significant degree.